摘要
高尿酸血症是由于体内尿酸产物增加或排泄减少而引起的以少尿、无尿、尿毒症为临床特征的综合征。近年来研究发现高尿酸血症与癌症的发生风险、复发、转移及预后有关。其机制可能与尿酸相关的慢性炎症反应及肿瘤细胞黄嘌呤氧化还原酶水平降低有关。目前高尿酸血症的治疗主要是抑制黄嘌呤氧化还原酶从而减少尿酸生成，但系统性抑制嘌呤氧化还原酶的不良反应受到越来越多关注。在相关癌症模型中进一步进行临床前机制研究以寻求最佳的管理高尿酸血症的策略是很有必要的。
Hyperuricemia is a syndrome caused by increased production or reduced excretion of uric acid which is characterized by oliguria, anuria, and uremia. Recent studies found that hyperuricemia was correlated with the risk, recurrence, metastasis, and prognosis of cancer. The mechanism may be uric acid associated chronic inflammation and decrease of xanthine oxidoreductase expression in cancer cells. Current treatment of hyperuricemia is to reduce the production of uric acid by inhibition of xanthine oxidoreductase, but the side effects of systemic inhibition of xanthine oxidoreductase received more and more attention. These unwanted side effects underscore the urgent need for mechanism based preclinical studies that can identify optimal strategies for management of hyperuricemia in relevant cancer models.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2016年第5期429-432,共4页
Chinese Journal of Endocrinology and Metabolism
基金
973计划子课题（2012CB517700）：国家自然科学基金面上项目（81070649）
